Henan Taloph Pharmaceutical Stock Co.,Ltd (SHA:600222)
China · Delayed Price · Currency is CNY 6.35
-0.18 (-2.76%)
Nov 13, 2026, 3:00 PM CST
SHA:600222 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,701 | 1,755 | 1,936 | 2,065 | 1,945 | 1,602 |
Other Revenue | 2.85 | 2.85 | 5.2 | 4.95 | 15.33 | 2.83 |
| 1,704 | 1,758 | 1,941 | 2,070 | 1,961 | 1,605 | |
Revenue Growth | -4.70% | -9.46% | -6.21% | 5.57% | 22.20% | 13.23% |
Cost of Revenue | 1,243 | 1,269 | 1,441 | 1,508 | 1,492 | 1,148 |
Gross Profit | 460.51 | 488.33 | 500.1 | 561.55 | 468.4 | 456.85 |
Selling, General & Admin | 237.95 | 258.36 | 307.58 | 339.5 | 317.51 | 246.89 |
Research & Development | 67.51 | 67.78 | 100.89 | 127.71 | 116.52 | 56.5 |
Other Operating Expenses | 13.75 | 9.93 | 8.63 | 6.54 | 8.42 | 2.59 |
Operating Expenses | 344.21 | 353.55 | 424.2 | 485.6 | 476.27 | 331.51 |
Operating Income | 116.3 | 134.78 | 75.9 | 75.94 | -7.87 | 125.34 |
Interest Expense | -14.95 | -56.32 | -59.64 | -54.37 | -64.63 | -83.84 |
Interest & Investment Income | 1.25 | 1.64 | 6.37 | 2.17 | 2.22 | 6.74 |
Other Non Operating Income (Expenses) | -39.33 | -4.6 | -1.51 | 10.8 | -1.56 | -2.46 |
EBT Excluding Unusual Items | 58.47 | 75.5 | 21.12 | 34.54 | -71.84 | 45.78 |
Gain (Loss) on Sale of Investments | 9.18 | 1.24 | 7.94 | -6.42 | -11.87 | -10.17 |
Gain (Loss) on Sale of Assets | -0.06 | -0.16 | 0.13 | 0.54 | 0.03 | -1.57 |
Asset Writedown | -0.64 | - | - | - | -0.15 | -29.9 |
Legal Settlements | - | - | - | - | -11.61 | -1.62 |
Other Unusual Items | 5.2 | 0.92 | 5.88 | 14.31 | 12.59 | 4.93 |
Pretax Income | 72.15 | 77.51 | 35.07 | 42.96 | -82.85 | 7.45 |
Income Tax Expense | 16.07 | 11.64 | -18.42 | -1.87 | -7.09 | 0.67 |
Earnings From Continuing Operations | 56.08 | 65.87 | 53.5 | 44.83 | -75.76 | 6.78 |
Minority Interest in Earnings | -5.17 | -5.87 | -2.97 | -1.27 | 3.56 | -0.78 |
Net Income | 50.91 | 60 | 50.53 | 43.56 | -72.2 | 6 |
Net Income to Common | 50.91 | 60 | 50.53 | 43.56 | -72.2 | 6 |
Net Income Growth | 8.42% | 18.75% | 16.00% | - | - | -79.50% |
Shares Outstanding (Basic) | 552 | 553 | 556 | 563 | 562 | 560 |
Shares Outstanding (Diluted) | 552 | 553 | 556 | 563 | 562 | 560 |
Shares Change | -0.21% | -0.63% | -1.12% | 0.07% | 0.36% | 2.52% |
EPS (Basic) | 0.09 | 0.11 | 0.09 | 0.08 | -0.13 | 0.01 |
EPS (Diluted) | 0.09 | 0.11 | 0.09 | 0.08 | -0.13 | 0.01 |
EPS Growth | 8.65% | 19.49% | 17.31% | - | - | -80.00% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 30.2 | 26.04 | -76.82 | 0.6 | -191.03 | 60.58 |
Free Cash Flow Per Share | 0.06 | 0.05 | -0.14 | 0.00 | -0.34 | 0.11 |
Dividend Per Share | - | 0.014 | 0.028 | 0.018 | - | 0.010 |
Dividend Growth | - | -50.00% | 55.56% | - | - | -37.50% |
Gross Margin | 27.03% | 27.78% | 25.76% | 27.13% | 23.89% | 28.47% |
Operating Margin | 6.83% | 7.67% | 3.91% | 3.67% | -0.40% | 7.81% |
Profit Margin | 2.99% | 3.41% | 2.60% | 2.10% | -3.68% | 0.37% |
Free Cash Flow Margin | 1.77% | 1.48% | -3.96% | 0.03% | -9.74% | 3.78% |
EBITDA | 167.53 | 186.25 | 127.69 | 127.23 | 39.37 | 169.33 |
EBITDA Margin | 9.83% | 10.60% | 6.58% | 6.15% | 2.01% | 10.55% |
D&A For EBITDA | 51.23 | 51.47 | 51.79 | 51.29 | 47.24 | 43.99 |
EBIT | 116.3 | 134.78 | 75.9 | 75.94 | -7.87 | 125.34 |
EBIT Margin | 6.83% | 7.67% | 3.91% | 3.67% | -0.40% | 7.81% |
Effective Tax Rate | 22.28% | 15.02% | - | - | - | 9.01% |
Revenue as Reported | 570.89 | 1,758 | 1,941 | 2,070 | 1,961 | 1,605 |
Advertising Expenses | - | 10.12 | 26.78 | 35.78 | 39.78 | 24.05 |